Open AccessA long-term follow-up study on biochemical and clinical biomarkers of response to interferon beta-1b treatment in relapsing-remitting multiple sclerosis
Author(s) -
Anna Pietrzak,
Alicja Kalinowska-Łyszczarz,
Krystyna Osztynowicz,
A Khamidulla,
Wojciech Kozubski,
Sławomir Michalak
Publication year - 2020
Publication title -
advances in clinical and experimental medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.486
H-Index - 27
eISSN - 2451-2680
pISSN - 1899-5276
DOI - 10.17219/acem/121063
Subject(s) - multiple sclerosis , medicine , socs3 , interferon , biomarker , disease , oncology , immunology , biology , suppressor , cancer , biochemistry
While interferon beta-1b (IFN-β-1b) is still a commonly used disease-modifying drug in the treatment of multiple sclerosis (MS), therapeutic possibilities are expanding, and treatment failure should be identified early. Markers to predict response to IFN-β-1b, either clinical or biochemical, are therefore urgently needed. Interferon-induced proteins, including viperin, suppressor of cytokine signaling 3 (SOCS3), ubiquitin specific peptidase-18 (USP18), and myxovirus resistance protein A (MxA), are possible markers of IFN-β-1b bioavailability and treatment response.